Policy & Regulation
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735
12 January 2026 - Biopharmaceutical company Viking Therapeutics Inc (NASDAQ: VKTX) on Monday announced publication of results from its Phase 2 VENTURE trial evaluating VK2735, a dual GLP-1/GIP recepto...
NewcelX reports positive biomaterial study results supporting stem cell islet delivery without immune suppression
12 January 2026 - Biotechnology company NewcelX Ltd (Nasdaq: NCEL) on Monday reported positive results from an international collaborative study evaluating advanced biomaterial strategies to support d...
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
12 January 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has submitted a Biologics License Application to the US Food and Drug Administrat...
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
12 January 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that the European Commission has approved Teizeild (teplizumab) to delay the onset of stag...
Futura Medical reports statistically significant female sexual function gains in WSD4000 study
12 January 2026 - Consumer healthcare group Futura Medical plc (AIM: FUM) reported on Monday positive results from an Early Feasibility Study of WSD4000, a topical treatment in development for female ...
GRIN Therapeutics doses first patient in global Phase 3 trial of investigational radiprodil for GRIN-NDD
12 January 2026 - GRIN Therapeutics Inc, a developer of precision therapeutics for neurodevelopmental disorders, announced on Friday that it has dosed the first patient in its global Phase 3 Beeline t...